Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide.
Hepatic venoocclusive disease (VOD) is the most common complication of cytoreductive therapy used for stem cell transplantation, but it is rarely encountered during induction treatment of acute leukemia. We describe a patient in whom severe clinical VOD developed shortly after induction treatment for acute monoblastic leukemia. Administration of intravenous defibrotide for 19 days induced complete resolution of the VOD. Further consolidation treatment was resumed including high-dose cytosine arabinoside without further complications.
Bairey
Osnat
O
Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. obairey@post.tau.ac.il
Kirgner
Ilia
I
Yakobi
Moshe
M
Hamdan
Ashraf
A
Ben-Ari
Ziv
Z
Shaklai
Mati
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000175:diagnosis / Q000188:drug therapy*; D008099:Liver / Q000473:pathology; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; D003561:Cytarabine; C036901:defibrotide; D003630:Daunorubicin